BICSTA (Best-In-Class Specific Targeting)™ Technology
BICSTA™ allows efficient production of asymmetric multispecific antibodies similar to the natural form of IgG. The technology offers superior yield in generating multispecific antibodies, enabling diverse configuration applications.
STARKINE (Selective Targeting Cytokine)™ Platform
STARKINE™ facilitates generation of novel cytokine variants through rational design and computational modeling.
Target Selection
Directed Evolution
AgonistorAntagonist
Cytokine Library
Affinity Modulation
Super agonist
Partial agonist
Antagonist
STARKINE™
Target Cell-Specific Cytokines
Antibody Targeting Cytokine
Mustbio utilizes BICSTA™ technology and STARKINE™ platform to develop next-generation immuno-oncology therapies that offer improved stability, efficacy, and therapeutic potential.
